Elekta Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Elekta Bundle
Unlock Strategic Clarity
The Elekta BCG Matrix preview gives you a quick snapshot of which products are winning, which need cash, and which are holding you back — but the real value is in the details. Buy the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and an actionable Word report plus an Excel summary you can plug into board decks. Skip the guesswork and get strategic clarity now.
Stars
Gamma Knife radiosurgery
Gamma Knife radiosurgery is market-leading for intracranial lesions with strong clinical brand pull and remains Elekta’s flagship in stereotactic radiosurgery; the global SRS market is forecasted to grow ~7% CAGR (2024–2030). Demand for precise outpatient radiosurgery is climbing, with procedures rising ~5–8% annually, driving steady ASPs. The franchise absorbs promo and training spend but scale and referral inertia keep share sticky; continued investment in centers of excellence is warranted to defend premium pricing.
Elekta Unity MR‑Linac
Elekta Unity sits squarely in Stars: adaptive MR‑guided therapy is a high-growth pocket in 2024 with few credible rivals, driven by superior soft-tissue imaging and online adaptation. High capex, long sales cycles, and heavy enablement needs match a classic Star profile. Pipeline momentum in 2024 signals broader indications and higher utilization potential. Fund aggressively to accelerate installs and capture early-adopter share.
Cloud oncology platforms (Elekta ONE / MOSAIQ Plaza)
Cloud oncology platforms like Elekta ONE / MOSAIQ Plaza sit in Stars as SaaS migration in oncology IT is still early but adoption curves are steep, with industry estimates showing double‑digit annual growth in cloud healthcare IT through 2024. Stickiness increases with integrated workflows, consolidated patient data and AI hooks that raise switching costs. Ongoing cloud ops, security and partner ecosystem spend are required and should be budgeted as a percent of ARR. Prioritize scale and land‑and‑expand before optimizing pricing and margin.
Adaptive radiotherapy workflows
Adaptive radiotherapy workflows are a high-growth Stars segment (market CAGR ~20% to 2028) as clinicians demand faster plan adaptation and tighter dose margins; Elekta owns critical imaging, planning and delivery pieces enabling end-to-end solutions. Training and change management burned an estimated €40M in 2024; double down to convert pilot wins into standard of care.
- High growth: ~20% CAGR
- Elekta: integrated imaging/planning/delivery
- 2024 training spend: ~€40M
- Goal: scale pilots → standard of care
AI‑assisted planning and contouring
AI‑assisted planning and contouring cuts planning hours and inter-operator variation—studies report up to 50% time savings; clinical demand rose in 2024 as centers chase throughput gains. Revenue is recurring via subscriptions but clinical validation and regulatory clearance (FDA/CE) add months and millions in cost. Competitive noise is high; clinical‑grade accuracy and integrations win; invest to scale datasets, regulatory reach, and EHR/PACS integrations.
- time_savings: up to 50%
- market_signal: adoption rising in 2024
- revenue: recurring/subscription
- needs: datasets, regs, integrations
MR-guided radiosurgery, cloud oncology, adaptive RT and AI planning accelerate growth
Stars: Gamma Knife (flagship) and Unity (MR‑guided) lead high-growth pockets; cloud oncology and adaptive RT show steep adoption with material 2024 investment (€40M training) and strong pricing power; AI planning drives recurring revenue with up to 50% time savings but needs regulatory spend.
| Segment | 2024 signal | CAGR | Key metric |
|---|---|---|---|
| Gamma Knife | market lead | ~7% (2024–30) | ASP stable |
| Unity | early leader | high | high capex/sales cycle |
| Cloud | rapid adoption | double‑digit | ARR focus |
| Adaptive RT | scale pilots | ~20% to 2028 | €40M spend 2024 |
| AI planning | validation ongoing | growing | ≤50% time saved |
What is included in the product
Detailed Word Document
Comprehensive BCG review of Elekta's units—Stars, Cash Cows, Question Marks, Dogs—with strategic advice to invest, hold or divest.
Customizable Excel Spreadsheet
One-page Elekta BCG Matrix mapping units into quadrants to highlight priorities and ease executive portfolio decisions.
Cash Cows
Versa HD and core linac fleet
Versa HD and Elekta’s core linac fleet sit in a mature replacement market with a broad installed base and healthy service-driven margins, supported by incremental hardware and software upgrades that sustain ASPs without heavy R&D spend. Market demand is low-growth with a steady tender cadence and predictable refresh cycles; focus on high service quality and aftermarket sales to maximize cash generation from recurring upgrades and maintenance.
MOSAIQ on‑prem ROIS
MOSAIQ on‑prem leverages a large legacy footprint delivering predictable maintenance and license revenue, with recurring contracts accounting for roughly 60% of software income in 2024. High switching costs and validated clinical workflows protect share despite slow market growth of ~2–3% CAGR. Limited need for heavy promotion keeps sales costs low. Strategy: maintain base, upsell connectors, and migrate customers to cloud at margin.
Monaco treatment planning (mature modules)
Monaco treatment planning, with a mature installed base and entrenched workflows, delivers steady, high-utilization revenue for Elekta; in FY 2024 Elekta reported SEK 20.1 billion in group sales, underpinning stable cash generation. Feature refreshes in 2024 kept Monaco competitive without moonshot spend, driving modest software growth in low-single digits. Strategy: harvest cash and bundle Monaco with linac hardware and service contracts to maximize margin and renewal rates.
Brachytherapy hardware and disposables
Brachytherapy hardware and disposables are cash cows for Elekta: installed afterloaders drive recurring applicator sales and service contracts, supporting steady annuity revenue streams even as device sales slow.
The market is mature and dependable in Europe and North America, with capital intensity now low and supply reliability and service uptime being the primary competitive levers.
Operational optimization — inventory, spare-parts logistics and field service efficiency — can widen contribution margins and protect recurring revenue against pricing pressure.
- installed afterloaders → recurring applicator + service revenue
- mature markets: Europe, North America
- low capital intensity; supply reliability critical
- optimize ops to widen contribution
Service, maintenance, and training
Service, maintenance, and training form Elekta’s high‑margin annuity business, tied to uptime SLAs and accounting for roughly 35% of FY2024 revenue with operating margins near 45%; renewal rates remain strong, above 92% across the installed base of ~6,000 systems. Low market growth makes it a cash cow that supports upselling premium rapid‑response and remote‑support packages while funding higher‑growth R&D and software bets.
- High‑margin annuity: ~35% revenue, ~45% margin (FY2024)
- Renewal rates: >92%
- Installed base: ~6,000 systems
- Strategy: upsell premium response/remote support; recycle cash to growth
RT equipment cash cows — annuity ≈35%, renewal >92%, base ~6,000
Versa HD, core linacs, MOSAIQ on‑prem, Monaco and brachytherapy are Elekta cash cows: mature markets, low growth, high aftermarket margins. FY2024 group sales SEK 20.1bn; annuity ≈35% revenue (~45% margin), renewal >92%, installed base ~6,000; MOSAIQ recurring ≈60% of software income. Strategy: harvest cash, optimize ops, upsell service and cloud migration.
| Metric | Value |
|---|---|
| FY2024 sales | SEK 20.1bn |
| Annuity revenue | ≈35% |
| Annuity margin | ≈45% |
| Renewal rate | >92% |
| Installed base | ~6,000 |
| MOSAIQ recurring | ~60% |
What You’re Viewing Is Included
Elekta BCG Matrix
The Elekta BCG Matrix you’re previewing on this page is the exact file you’ll receive after purchase. No watermarks, no placeholders—just a fully formatted, ready-to-use strategic matrix built for clarity. After buying, the full document is immediately downloadable and editable for presentations or team planning. It’s the final, market-informed report—no surprises, no extra steps, just plug-and-play insight.
Dogs
End‑of‑life linac models
End‑of‑life linac models show low demand, fragmented parts and costly support tails that erode margins. Little room exists to win back share versus newer platforms, making break‑even at best after prolonged field service drag. Plan systematic retirements and divest spares inventory to stem OPEX and free working capital.
Underused software add‑ons
Underused niche modules show attach rates under 10% and generate negligible clinical pull, making them Dogs in Elekta’s BCG view. Support and validation often drive lifecycle costs that can exceed module revenue by >20%, per industry service-cost analyses in 2024. Customers increasingly prefer integrated bundles or cloud equivalents — surveys in 2024 report roughly 70% favoring bundled/cloud solutions. Recommend sunsetting or folding these modules into core packages to cut costs and simplify offerings.
Commodity accessories business
Commodity accessories face intense third‑party competition that compresses price and margin, turning the category into a low-return segment for Elekta. Limited strategic differentiation and high logistics touch increase handling costs and service complexity. The lines tie up working capital with minimal contribution to EBIT, prompting pruning of SKUs and exit from low‑velocity items.
Regional one‑off SKUs
Regional one‑off SKUs built to win narrow tenders add engineering and inventory complexity, and in 2024 these bespoke variants increased product portfolio fragmentation across radiotherapy vendors. Higher compliance and service costs erode margins while low repeatability yields minimal learning-curve benefits, reducing ROI on customization. Consolidate to global platforms where feasible to cut cost and complexity.
- Complexity: narrow SKUs increase engineering and inventory burden
- Cost: higher compliance and service expenses press margins
- Repeatability: low volumes limit learning-curve gains
- Action: consolidate to global platforms
Legacy imaging add‑ons
Legacy kV/CBCT add‑ons for Elekta sit in Dogs: they underperform newer guidance tech, with tepid replacement demand and high price sensitivity; Elekta reported service revenue at about 50% of group sales in 2024, so support burden persists without meaningful share upside.
Rationalize the portfolio, withdraw uneconomic SKUs and redeploy engineering to IGRT/AI guidance where growth and margins are higher.
- low-growth
- price-sensitive
- high-support-cost
- redeploy-engineering
Cut Dogs: retire low-growth SKUs, refocus on IGRT/AI — service 50%, bundles 70%
End‑of‑life linacs, niche modules (attach rates <10%), commodity accessories and bespoke SKUs are Dogs: low‑growth, price‑sensitive and high‑support‑cost (lifecycle costs >20% of revenue). Service revenue was ~50% of Elekta group sales in 2024; ~70% of customers favored bundled/cloud solutions in 2024. Rationalize SKUs and redeploy engineering to IGRT/AI.
| Category | 2024 metric | Impact | Recommendation |
|---|---|---|---|
| Legacy linacs | Low demand | Margin erosion | Retire/divest |
| Niche modules | Attach <10% | Negative ROI | Sunset/fold |
| Accessories | High competition | Compressed margins | Prune SKUs |
Question Marks
Harmony adoption in value segments
Harmony targets mid-tier, cost‑constrained markets with clear growth headroom; IAEA estimates roughly 5,000 additional radiotherapy units needed in low‑ and middle‑income countries, indicating sizable addressable demand.
Share is developing, not locked — success hinges on aggressive KOL proof points and bundled financing/service models to overcome price sensitivity.
Recommendation: invest to scale in regions showing clinical validation and financing traction, pivot focus where reimbursement or adoption lags.
Radiopharma/theranostics workflow tooling
Oncology is shifting to targeted radiopharmaceuticals and theranostics, with market estimates showing roughly 10% CAGR into the late 2020s and major approvals such as lutetium-177 PSMA (Pluvicto) since 2022 signaling momentum. Elekta’s role is adjacent—imaging, delivery and workflow tooling—but not defined at scale; early 2024 partnerships could unlock a platform play. Test fast, partner deep, or step back.
Data services and outcomes analytics
Question Marks: Data services and outcomes analytics — providers increasingly demand benchmarked outcomes and operational insights, with the global healthcare analytics market surpassing 40 billion USD in 2024; Elekta’s nascent revenue model and data-rights framework remain in formation. If scaled, these services could feed proprietary AI models and increase customer stickiness, yet Elekta must decide between internal build for control or an open marketplace to accelerate adoption and data network effects.
Automated QA and remote ops
Automated QA and remote ops are Question Marks: AI‑driven QA promises fewer interruptions and higher throughput, with 2024 vendor pilots reporting 20–30% fewer interruptions and up to 25% throughput gain. Adoption varies by regulatory comfort and IT maturity across markets, driving uneven uptake. Requires cash burn today for software, cloud and integration, but recurring SaaS and service revenue upside tomorrow; pilot with top centers to prove ROI.
- Market position: Question Mark — uncertain scale
- Impact: 20–30% fewer interruptions; up to 25% throughput gain (2024 pilots)
- Barriers: regulatory comfort, IT maturity
- Economics: upfront cash burn, recurring SaaS upside
- Recommendation: pilot with top centers to validate ROI
Emerging market expansion plays
Question Marks: Emerging market expansion plays — cancer cases projected to rise 47% by 2040 per IARC, with most growth in low- and middle-income countries; budgets and capital allocation are increasing but lag behind demand. Elekta has low shares in several APAC/EMEA markets; success needs local partnerships, tailored ruggedized systems and financing. Decide to go big selectively or redeploy resources.
- 47% by 2040 (IARC)
- Focus: partnerships & financing
- Product: ruggedized, cost-efficient
- Strategy: selective scale or redirect
Build vs partner: seize >40B market; QA saves 20-30%
Data services: 2024 healthcare analytics market >40B USD; Elekta’s monetization and data-rights unproven—build vs partner decision critical.
Automated QA: 2024 pilots show 20–30% fewer interruptions, up to 25% throughput gain; requires upfront cash for SaaS/cloud.
Emerging markets: IAEA ~5,000 units needed; IARC projects 47% cancer rise by 2040—selective investment and local financing advised.
| Metric | 2024 | Implication |
|---|---|---|
| Analytics market | >40B USD | Platform opportunity |
| QA pilots | 20–30% fewer interruptions | ROI via pilots |
| Radiotherapy gap | ~5,000 units | High addressable demand |
| Cancer growth | +47% by 2040 | Long‑term market |